Jianpi Bushen Recipe affects epithelial-mesenchymal transition in hepatocellular carcinoma through TGF-β and Twist

Backgroud:To explore the effects of Jianpi Bushen Recipe on the epithelial-mesenchymal transition(EMT)of nude mice with transplanted human liver cancer SK-HEP-1 cells.Methods:To establish models with transplanted liver cancer cells,nude mice were divided randomly into three groups:blank group,traditional Chinese medicine(TCM)group and control group.They were given normal saline,Jianpi Bushen Recipe and solafeni through administration by gavage for four weeks.The expression of TGF-β and twist mRNA were detected by real-time PCR.The expression of E-cadherin was detected by Western blot.Results:Compared with the blank group,the expression of transforming growth factor-P(TGF-β)mRNA and twist mRNA in the TCM group and the control group decreased significantly(P<0.05).There was no significant difference between the two groups(P>0.05).The expression of E-cadherin protein in TCM group and control group increased significantly(P<0.01).There was no significant difference between the two groups(P>0.05).Conclusion:Jianpi Bushen Recipe can inhibit the EMT of liver cancer SK-HEP-1 cells in vivo by down-regulating the expression of TGF-β/twist signaling and indirectly up-regulating E-cadherin expression in transplanted liver cancer tissue,indicating the potential of Jianpi Bushen Recipe to inhibit invasion and metastasis of liver cancer.

Efficacy of Jianpi Bushen Huatan Recipe in the treatment of obese polycystic ovarian syndrome:A meta-analysis

Objective:To evaluate the effects of Jianpi Bushen Huatan Recipe on sex hormone levels、blood lipid and blood glucose levels in the treatment of obese poly-cystic ovarian syndrome(PCOS).Methods:Data bases including the CNKI、Vip、Wanfang were searched.Studies about randomized controlled trials(RCT)of the effectiveness of Jianpi Bushen Huatan Recipe Combined with Metformin in the Treatment of obese PCOS were included.Rev Man 5.3 software was used for meta analysis.Results:A total of 11 studies were enrolled.Meta-analysis showed that Jianpi Bushen Huatan Recipe Combined with Metformin significantly improved the clinical total effective rate of patien ts(RR=1.32,95%CI(1.20,1.45),P<0.00001);reduced the body mass index(BMI)(SMD=-0.92,95%CI(-1.13,-0.72),P<0.00001),luteinizing hormone(LH)(SMD=-1.00,95%CI(-1.37,-0.62),P<0.00001),LH/FSH(SMD=-1.03,95%CI(-1.34,-0.71),P<0.00001),insulin resistant index(HOMA-IR)(SMD=-0.59,95%CI(-0.79,-0.40),P<0.00001),fasting insulin(FIN)(SMD=-0.77,95%CI(-1.19,-0.35),P=0.0003),total cholesterol(TC)(SMD=-0.63,95%CI(-0.88,-0.38),P<0.00001),triglycerides(TG)(SMD=-0.60,95%CI(-0.83,-0.36),P<0.00001),highdensity lipoprotein(HDL)(SMD=-0.41,95%CI(-0.51,-0.32),P<0.00001).However,there was no statistically significant in waist-to-hip ratio(WHR),follicle stimulating hormone(FSH),fasting blood sugar(FBS)and low density lipoprotein(LDL).Conclusions:Jianpi Bushen Huatan Recipe Combined with Metformin in the treatment of obese PCOS has an advantage in improving the sex hormone level,blood lipid and blood glucose level,and is superior to metformin alone.

Effect of Acupuncture and Jianpi Bushen Decoction on Ovarian Function and Metabolic Disorders in Patients with PCOS

Objective:To study the effects of acupuncture combined with Jianpi Bushen Decoction on ovarian function and metabolic disorders in patients with polycystic ovary syndrome(PCOS).Methods:A total of 100 PCOS patients admitted in our hospital from October 2018-January 2020 were selected,and the patients were divided into the Jianpi Bushen Decoction group and the combined group with 50 patients each according to a completely random method.The patients in the Jianpi Bushen Decoction group were given Jianpi Bushen Decoction;the combined group was given acupuncture on the basis of the Jianpi Bushen Decoction group.Detection of follicle stimulating hormone(FSH),testosterone(T),pituitary prolactin(PRL),estradiol(E2),fasting insulin(FIN),fasting blood glucose(FBG),insulin resistance index(HOMA-IR),triglyceride Ester(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),endometrial thickness,ovarian volume,number of ovarian sinus follicles,C-reactive protein(CRP),procalcitonin(PCT).Statistical treatment is effective.Results:After treatment,FSH,T,PRL,FIN,FBG,HOMA-IR,TG,TC and LDL-C were lower in Jianpi Bushen Decoction group,and E2 and HDL-C levels were higher than Jianpi Bushen Decoction group(P<0.05).The endometrial thickness of the combined group was higher than that of Jianpi Bushen Decoction group,and the ovarian volume and the number of ovarian sinus follicles were lower than that of Jianpi Bushen Decoction group(P<0.05).The levels of CRP and PCT in the combination group were lower than those in the Jianpi Bushen Decoction group(P<0.05).The total effective rate of patients in combination group was higher than that in Jianpi Bushen Decoction group(P<0.05).Conclusion:Acupuncture combined with Jianpi Bushen Decoction has significant therapeutic effects on patients with PCOS,effectively improves patients'ovarian function,improves endocrine and metabolic disorders,and reduces inflammatory reactions,which deserves clinical promotion.

Effect of Jianpi Bushen Sequential Formula on Adjuvant Chemotherapy of Colon Cancer:Study Protocol for a Randomized Controlled Trial

Background The side effects of chemotherapy-induced nausea and vomiting(CINV)and myelosuppression reduce the cancer patients’adherence to chemotherapy.Many Chinese patients choose Chinese medicine(CM)during chemotherapy to reduce side effects;however,the evidence is lacking.The efficacy of a CM herbal treatment protocol,Jianpi Bushen Sequential Formula(健脾补肾续贯方,JBSF)will be evaluated on chemotherapy completion rate among patients with colon cancer.Methods A multi-center double-blind randomized controlled trial(RCT)will be conducted on 400 patients with colon cancer who will receive 8 cycles of adjuvant chemotherapy with oxaliplatin and capecitabine(CAPEOX).Patients will be randomized 1:1 to receive the JBSF or placebo formula.The primary outcome is the overall chemotherapy completion rate.The secondary outcomes include individual chemotherapy completion rate,4-cycle completion rate of chemotherapy,time to treatment failure,relative dose intensity and treatment toxicity.Follow-up visits will be scheduled before every and after last chemotherapy.Discussion This study will provide evidence on whether JBSF can improve the chemotherapy completion rate and reduce side effects among patients with colon cancer.(Trial registration:Clinical Trials.gov,No.NCT03716518)。

Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction

Objective: To evaluate the effect and safety of low-dose of apatinib and S-1 combined with Jianpi Bushen Jiedu Decoction(JBJD) in patients with metastatic colorectal cancer(mCRC) who have failed second or above lines treatment, in order to provide more treatment option for mCRC patients by integrated medicine. Methods: Thirteen patients were selected from a single-arm, open-label clinical study from April 2019 to September 2020. The patients were treated with low-dose apatinib(250 mg, once a day) and S-1(20 mg, twice a day) combined with JBJD for at least one cycle and were followed up to August 2021. The primary endpoint was disease progression-free survival(PFS). Disease control rate(DCR), objective response rate(ORR), and overall survival(OS) of patients were observed as the secondary endpoints. Adverse events were recorded as well. Results: The average age of the 13 patients was 56.5±13.0 years and 76.9% were male. The median PFS and median OS were 4.6 and 8.3 months, respectively. The ORR was 7.7%(1/13) while the DCR was 61.5%(8/13). The common adverse events were hypertension, proteinuria, elevated transaminase, and thrombocytopenia. One patient experienced thrombocytopenia of grade 3. Conclusions: Patients with mCRC after failure of the second or above lines of treatment may potentially benefit from the treatment of low-dose apatinib and S-1 combined with JBJD because of its similar effect as the standard dose of target therapy and relatively better safety.(Registration No. ChiCTR1900022673)

Effect of Yiqi Jianpi Bushen Recipe (益气健脾补肾方) in Reducing Nephrotoxicity of Cisplatin

Objective: To observe the clinical effect of Yiqi Jianpi Bushen recipe (YQJPBS, 益气健脾补肾方) in antagonizing nephrotoxicity and hematological toxicity by cisplatin (CDDP). Methods: The patients with different types of carcinomas were divided into two groups. One group was treated by western medicine (WM), i.e. cisplatin combined with diuretic therapy. The other group by Chinese medicine (CM). One day before chemotherapy, YQJPBS was given orally. Urinary enzyme (NAG, γ-GT, ALP) and serum erythropoietin (Epo) were used as the key monitoring indicator. Results: The early renal damage by CDDP remains near proximal convoluted tubule, which leads to the rising of urinary enzyme. So urinary enzyme of the CM group was obviously lower than that of the WM group. The lesion of renal interstitial cells that produce Epo did not cause the serum Epo of WM group to rise obviously 15 days later. As a result there was 40% patients whose RBC and Hb became lower than the standard count. While serum Epo of CM group was higher than that of WM group, only 5% patients in the CM group had their RBC and Hb lowered. Conclusion: YQJPBS can effectively antagonize nephrotoxicity and hematological toxicity induced by CDDP.

Effect of Telbivudine tablet combined Jianpi Bushen recipe on HBV specific cytotoxic T lymphocyte and HBe Ag seroconversion in patients with HBe Ag positive chronic hepatitis B

Objective To explore the effect of Telbivudine(LDT)Tablet combined with Jianpi Bushen Recipe(JBR)on serum hepatitis B virus(HBV)specific cytotoxic T lymphocyte(CTL)and HBe Ag seroconversion in chronic hepatitis B(CHB)patients.Methods Totally90 HBe Ag-positive and human leukocyte antigen(HLA)-A2 positive CHB patients were randomly assigned to

Effect of Jianpi Bushen formula on aromatase-inhibitor-associated bone loss after menopause

OBJECTIVE: To investigate the effect of Jianpi Bushen(JPBS) formula on aromatase inhibitor(AI)-associated bone loss after menopause.METHODS: Six-month-old female rats were randomly divided into 6 groups: a sham group, an ovariectomized(OVX) group, an OVX treated with exemestane and 3 OVX groups each treated with a different dose of JPBS formula. Bone mineral density(BMD) at the lumbar vertebrae, histology, bone markers and serum levels of estrogen were assessed. Furthermore, a cohort study was conducted in 130 postmenopausal women with breast cancer that had undergone treatment with AIs. The subjects were given JPBS + caltrate D or caltrate D only, administered orally. BMD at the lumbar vertebrae and femoral neck and bone markers were evaluated in both control and herbal treatment groups at baseline and 12 months.RESULTS: Experimental results indicated that a high dose of JPBS significantly increased the trabecular bone area percentage(Tb.Ar %) and broadened the trabecular thickness(Tb.Th). The JPBS formula enriched the carboxyterrninal propeptide of type ipmcollagen and increased serum estrogen level significantly. The clinical investigation revealed that bone loss was decreased in the group treated with JPBS vs control(BMD T score at lumbar vertebrae, 3.9% increased vs 14.58% decreased, respectively, P = 0.004 and BMD T score on femoral neck, 1.8% decreased vs 22.45% decreased, respectively, P = 0.008). Besides, JPBS formula elevated Nmiddle osteocalcin and decreased type Ⅰ collagen cross-linked C-terminal telopeptide.CONCLUSION: JPBS formula prevented aromatase-inhibitor-associated bone loss after menopause by inhibiting bone resorption and promoting bone formation.

Jianpi Qingchang Bushen decoction improves inflammatory response and metabolic bone disorder in inflammatory bowel disease-induced bone loss

BACKGROUND Bone loss and osteoporosis are commonly described as extra-intestinal manifestations of inflammatory bowel disease(IBD).Jianpi Qingchang Bushen decoction(JQBD)is a prescription used in clinical practice.However,further studies are needed to determine whether JQBD regulates the receptor activator of nuclear factor kappa B(NF-κB)(RANK)/receptor activator of NF-κB ligand(RANKL)/osteoprotegerin(OPG)pathways and could play a role in treating IBD-induced bone loss.AIM To evaluate the therapeutic effect of JQBD in IBD-induced bone loss and explore the underlying mechanisms.METHODS An IBD-induced bone loss model was constructed by feeding 126-to-8-wk-old interleukin-10(IL-10)-knockout mice with piroxicam for 10 d.The mice were randomly divided into model and JQBD groups.We used wild-type mice as a control.The JQBD group was administered the JQBD suspension for 2 wk by gavage,while the control and model groups were given normal saline at the corresponding time points.All mice were killed after the intervention.The effect of JQBD on body weight,disease activity index(DAI),and colon length was analyzed.Histopathological examination,colon ultrastructure observation,and micro-computed tomographic scanning of the lumbar vertebrae were performed.The gene expression of NF-κB,tumor necrosis factor-α(TNF-α),IL-1β,IL-6,and IL-8 in the colon was evaluated by real-time polymerase chain reaction.Colon samples were assessed by Western blot for the expression of RANKL,OPG,RANK,and NF-κB proteins.RESULTS The model group lost body weight,had a shorter colon,and showed a dramatic increase in DAI score,whereas JQBD had protective and therapeutic effects.Treatment with JQBD significantly improved inflammatory cell infiltration and reduced crypt abscess and ulcer formation.Threedimensional imaging of the vertebral centrum in the model group revealed a lower bone mass,loose trabeculae,and“rod-shaped”changes in the structure compared to the control group and JQBD groups.The bone volume/total volume ratio and bone mineral density were significantly lower in the model group than in the control group.JQBD intervention downregulated the NF-κB,TNF-α,IL-1β,IL-6,and IL-8 m RNA expression levels.The RANKL and OPG protein levels were also improved.CONCLUSION JQBD reduces inflammation of the colonic mucosa and inhibits activation of the RANK/RANKL/OPG signaling pathway,thereby reducing osteoclast activation and bone resorption and improving bone metabolism.

Clinical application of Bushen Jianpi Gutai Decoction in threatened abortion

Objective:To discuss the clinical application of the"seven,five and three"odd-numbered law theory and analyze the effect on serum sex hormone level.Methods:A total of 100 patients with early threatened abortion admitted from January 2021 to October 2021 were randomly divided into study group and control group,with 50 patients in each group.Patients in the control group were treated with dydrogesterone tablets,while patients in the study group were treated with Bushen JianpiGutai Decoction combined with dydrogesterone tablets.Clinical efficacy and progesterone level before and after treatment were observed and compared between the two groups,as well as clinical symptom relief time of the two groups,including hemostasis time,abdominal pain relief time and lumbar acid relief time,and sex hormone level of the two groups were observed and compared.Results:The clinical efficacy was significantly better than control patients(P<0.05),no significant difference in progesterone level comparison before treatment(P>0.05),significantly better than control patients(P<0.05),hemostasis,abdominal pain remission and waist acid remission were significantly shorter than control patients(P<0.05),and both significantly better sex hormone levels after treatment(P<0.05).Conclusion:Traditional Chinese medicine has certain advantages in the treatment of threatened abortion,odd-numbered law theoryguidesthe regulation of Yin and Yang in the female menstrual cycle and reproductive function is mainly the regular change of Yin and Yang.Under the guidance of"seven,five,three"odd-numbered law theoryof Traditional Chinese medicine master Xia Guicheng,master the key date and the best time of its transformation,regulate Yin and Yang in the female body,to prevent the occurrence and development of menstrual diseases and adverse childbirth.Bushen Jianpi Gutai decoction can effectively treat threatened abortion,significantly improve the clinical symptoms,improve the level of serum sex hormone,worthy of clinical promotion.

Effect of Combination of Bushen Jianpi Recipe (补肾健脾方) and Erythropoietin on Serum Tumor Necrosis Factor a in Patients with Anemia

Objective: To study the effect of treatment of renal anemia by combination of Bushen Jianpi Recipe (补贤健脾方, BJR, a Chinese experienced recipe for supplementing Shen and supporting Pi) and low dosage erythropoietin (EPO), and the influence of treatment on change of serum tumor necrosis factor α (TNF-α) so as to explore the possible mechanism of integrative Chinese and Western medicine (ICWM) in treating renal anemia. Methods: Patients with renal anemia were randomly divided into two groups, the ICWM group and the control group, supporting treatment such as dialysis, supplementing of ferrous, foliac acid and vitamin B12, was given to both groups. Additionally, to the ICWM group, 50 IU/kg of EPO subcutaneous injection for twice every week, and oral intake of BJR, one dose per day taken in two parts, were given, and to the control group, EPO alone, 50IU/kg by subcutaneous injecting, 3 times perweek, was given. The therapeutic course for two groups was 3 months. Blood levels of hemoglobin (Hb), hematocrit (Hct), TNF-α were measured before treatment and the therapeutic effect was observed. Results: After treatment, the levels of Hb and Hct increased significantly in both groups (P<0. 01) , comparison between the two groups in Hb and Hct after treatment for 3 months showed significant difference (P<0. 05). The serum level of TNF-α was markedly higher than normal range in both groups before treatment, it significantly lowered after treatment in the ICWM group (P< 0.05), but unchanged in the control group. Conclusion: Combination of BJR and EPO could significantly inhibit the production of TNF-α, this may be an important factor for ICWM in effectively improving sensitivity to EPO.Original article on CJITWM (Chin) 2004;24 (2): 106

补肾健脾方治疗卵巢储备功能减退相关不孕脾肾两虚证临床观察

目的:研究补肾健脾方治疗卵巢储备功能减退相关不孕脾肾两虚证的临床疗效。方法:纳入60例卵巢储备功能减退相关不孕脾肾两虚证患者,采用随机数字法分成治疗组和对照组,每组30例。治疗组患者给予补肾健脾方治疗,对照组患者给予芬吗通治疗,两组均连续治疗6个周期。检测性激素指标[基础卵泡刺激素(bFSH)、基础黄体生成素(bLH)、血清雌二醇(E2)、抗米勒管激素(AMH)]、超声指标[卵巢体积、窦卵泡(AFC)数量],比较两组患者中医证候积分、总有效率、妊娠率、流产率,并监测安全性指标。结果:治疗组总有效率为79.31%(23/29),对照组总有效率为82.14%(23/28),差异无统计学意义(P>0.05)。经过6个月经周期治疗后,两组治疗后中医证候积分、bFSH均较治疗前下降(P<0.05),AMH较治疗前升高(P<0.05),且治疗组优于对照组(P<0.05)。治疗组治疗后bLH较治疗前下降(P<0.05);对照组治疗前后bLH比较,差异无统计学意义(P>0.05)。两组治疗后E2较治疗前有明显升高(P<0.05),两组患者治疗后E2比较,差异无统计学意义(P>0.05)。治疗组治疗后卵巢体积明显增大(P<0.05),窦卵数量明显增多(P<0.05),治疗组明显优于对照组(P<0.05)。治疗组妊娠率[34.48%(10/29)]高于对照组[21.43%(6/28)](P<0.05),治疗组流产率[10.00%(1/10)]低于对照组[33.30%(2/6)(P<0.05)]。两组患者治疗前后安全性指标未发现异常,未发生不良反应。结论:补肾健脾方能安全有效地治疗卵巢储备功能减退相关不孕脾肾两虚证,改善卵巢相关激素水平,提高妊娠率,降低流产率,缓解临床症状。

补肾健脾活血方调控Apaf-1/CHOP-Caspase-9/Bcl-2通路抑制成骨细胞氧化应激

目的探讨补肾健脾活血方对减轻大鼠成骨细胞氧化应激损伤和调控线粒体介导的细胞凋亡的机制。方法提取大鼠原代成骨细胞,通过CCK8实验检测补肾健脾活血方干预下对成骨细胞增殖活性的影响、碱性磷酸酶(alkaline phosphatase,ALP)染色检测成骨细胞ALP活性、茜素红染色检测成骨细胞的矿化情况、实时定量PCR检测Apaf-1和CHOP基因的mRNA表达、蛋白质印迹检测Caspase-9和Bcl-2蛋白表达量。结果CKK8实验和碱性磷酸酶染色表明氧化应激损伤的大鼠成骨细胞增殖活性显著降低,成骨分化受抑制,同时Apaf-1和CHOP的mRNA表达以及Caspase-9的蛋白表达明显增加(P≤0.01),Bcl-2蛋白表达则显著减少(P≤0.01);经补肾健脾活血方干预后,成骨细胞增殖活性得到明显的增强、成骨分化增加,Apaf-1和CHOP的mRNA及Caspase-9的蛋白表达均显著减少(P<0.05),而Bcl-2的蛋白表达则显著升高(P≤0.0001)。结论补肾健脾活血方可以促进成骨细胞增殖和成骨分化,显著降低Apaf-1和CHOP的mRNA及Caspase-9的蛋白表达,升高Bcl-2的蛋白表达量。补肾健脾活血方在减轻成骨细胞的氧化应激损伤和调控线粒体介导的细胞凋亡中起着重要作用。

健脾补肾活血汤辅助IVF-ET对不孕患者卵巢储备功能、胚胎质量及妊娠率的影响

目的:探讨健脾补肾活血汤辅助体外受精-胚胎移植(IVF-ET)对不孕患者卵巢储备功能、胚胎质量及妊娠率的影响。方法:选取医院2019年11月~2022年11月68例不孕症患者,随机数字表法分为两组,均34例。对照组采用IVF-ET治疗,观察组采用健脾补肾活血汤辅助IVF-ET治疗。观察疗效,对比治疗前后中医证候积分、卵巢储备功能、胚胎质量及妊娠情况。结果:观察组较对照组总有效率升高(P<0.05);治疗后,观察组较对照组中医证候积分降低(P<0.05);治疗后,观察组较对照组卵泡最大直径、子宫内膜厚度均升高,卵巢体积降低(P<0.05);观察组较对照组可用胚胎数、优质胚胎数均升高(P<0.05);观察组较对照组生化妊娠率、临床妊娠率均升高(P<0.05)。结论:健脾补肾活血汤辅助IVF-ET治疗不孕症的疗效显著,能缓解患者症状,改善卵巢储备功能,提高胚胎质量及妊娠率。

基于相关细胞凋亡途径探讨补肾健脾方调控大鼠卵巢储备功能减退的机制研究

目的观察补肾健脾方对环磷酰胺诱导的卵巢储备功能减退大鼠模型卵巢功能的影响,并基于肿瘤坏死因子诱导相关细胞凋亡途径探讨补肾健脾方调控大鼠卵巢储备功能减退的机制研究。方法60只动情周期正常的健康雌性SD大鼠,随机分成正常组10只和造模组50只,造模组采用环磷酰胺75 mg/kg单次腹腔注射造模。造模成功的大鼠再随机分为模型组、西药组[戊酸雌二醇0.103 mg/(kg·d)+黄体酮胶囊2.575 mg/(kg·d)]、补肾健脾方低剂量组[3.21 g/(kg·d)]、补肾健脾方中剂量组[6.43 g/(kg·d)]、补肾健脾方高剂量组[12.85 g/(kg·d)],每组10只。正常组及模型组均予等体积蒸馏水灌胃,每组干预1次/d,干预14 d。检测各组大鼠动情周期、体质量、卵巢脏器指数、子宫脏器指数;ELISA法检测大鼠血清肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、γ干扰素(interferon-γ,IFN-γ)含量;免疫荧光法检测大鼠卵巢颗粒细胞内B细胞淋巴瘤-2(B-cell lymphoma-2,Bcl-2)、Bcl-2相关X蛋白(Bcl-2 associated X protein,Bax)蛋白表达情况;HE染色检测卵巢组织病理情况;Western blot法检测卵巢磷酸化蛋白激酶B(posphorylated-proteinkinase B,p-AKT)、磷酸化哺乳动物雷帕霉素靶蛋白(p-mammalian target of rapamycin,p-mTOR)、自噬蛋白苄氯素-1(Beclin-1)表达情况。结果与正常组比较,模型组大鼠动情周期紊乱,可见卵巢结构紊乱、各级卵泡数量不同程度的减少、未见成熟卵泡,卵巢间质中见到明显炎细胞浸润;大鼠体质量、卵巢脏器指数和子宫脏器指数无明显变化;血清TNF-α、IFN-γ水平升高(P<0.05,P<0.01);卵巢颗粒细胞Bcl-2、Bax、Beclin-1蛋白表达水平升高(P<0.05,P<0.01),p-AKT、p-mTOR蛋白表达水平降低(P<0.01)。与模型组比较,西药组及补肾健脾方低、中剂量组血清TNF-α、IFN-γ水平降低(P<0.05,P<0.01);补肾健脾方中剂量组Bax蛋白表达水平降低(P<0.05);补肾健脾方高剂量组Bcl-2蛋白阳性表达升高(P<0.05);西药组、补肾健脾方低剂量组Beclin-1蛋白表达水平降低(P<0.05,P<0.01),p-AKT、p-mTOR蛋白表达水平升高(P<0.01)。与西药组比较,补肾健脾方高剂量组TNF-α水平升高(P<0.01);补肾健脾方低、高剂量组IFN-γ水平降低(P<0.05);补肾健脾方低剂量组Bax蛋白表达水平升高(P<0.05),补肾健脾方中剂量组Bcl-2蛋白水平表达升高(P<0.05);补肾健脾方中、高剂量组Beclin-1蛋白表达水平升高(P<0.05,P<0.01),p-AKT、p-mTOR蛋白表达水平降低(P<0.01)。结论补肾健脾方可改善卵巢病理变化、提高卵巢储备功能,其机制可能通过抑制肿瘤坏死因子TNF-α、IFN-γ表达,增强Bcl-2蛋白表达水平,降低Bax蛋白表达水平,激活mTOR通路抑制大鼠卵巢颗粒细胞的自噬与凋亡,从而改善环磷酰胺造模所致的大鼠卵巢储备功能减退的影响。

补肾健脾通络方治疗老年衰弱综合征临床疗效观察

目的观察补肾健脾通络方治疗老年衰弱综合征临床疗效及安全性。方法研究纳入2021年1月—2022年6月收治的老年衰弱综合征患者共计102例,以随机数字表法将患者分为对照组与观察组,每组51例,对照组患者采取临床常规治疗,观察组患者采取常规治疗结合补肾健脾通络方治疗。观察各组数据:治疗总有效率、治疗前后患者中医证候总积分变化及Fried表型衰弱量表(frailty phenotype,FP)评分变化及白介素-6(interleukin 6,IL-6)、超敏C反应蛋白(C-ReactiveProtein,hs-CRP)水平变化、握力变化及起立-行走计时测试(Timed Up and Go test,TUG)变化、5次坐立试验(five-times-sit-to-stand test,FTSST)变化、步速变化、体质指数(Body Mass Index,BMI)变化及四肢骨骼肌质量指数(appendicular skeletal muscle mass index,ASMI)变化、简易精神状态评分(Mini-mental State Examination,MMSE)变化、匹兹堡睡眠指数(Pittsburgh sleep quality index,PSQI)评分变化、日常生活能力(Activity of Daily Living,ADL)评分变化、微型营养评估(mini nutritionaal assessment,MNA)评分变化、患者治疗满意度、不良反应。结果观察组患者治疗总有效率比对照组高[96.08%(49/51)vs84.31%(43/51)],P<0.05;治疗前,各组患者中医证候总积分、FP评分、IL-6、hs-CRP水平、握力、TUG测试结果及FTSST测试结果、步速、BMI、ASMI、MMSE评分、PSQI评分、ADL评分、MNA评分比较,P>0.05,治疗后各组患者中医证候总积分、FP评分、IL-6、hs-CRP水平、握力、TUG测试结果及FTSST测试结果、步速、BMI、ASMI、MMSE评分、PSQI评分、ADL评分、MNA评分均改善,观察组患者治疗后中医证候总积分、FP评分、IL-6、hs-CRP水平、握力、TUG测试结果及FTSST测试结果、步速、BMI、ASMI、MMSE评分、PSQI评分、ADL评分、MNA评分均优于对照组患者,P<0.05;观察组患者治疗满意度高于对照组[98.04%(50/51)vs84.31%(43/51)],P<0.05;观察组与对照组不良反应率均较低,且可自行缓解,P>0.05。结论补肾健脾通络方治疗老年衰弱综合征临床疗效显著,能缓解衰弱综合征患者的临床症状,抑制患者机体炎性反应,增加肌肉质量,改善睡眠,提高生活质量,且无不良反应,较为安全可靠,值得应用。

健脾补肾活血解毒方联合地西他滨治疗骨髓增生异常综合征的多中心随机对照研究

目的观察健脾补肾活血解毒方联合地西他滨(Decitabine,DAC)治疗骨髓增生异常综合征的临床疗效及安全性。方法收集2017年1月至2019年9月在上海中医药大学附属市中医医院、上海中医药大学附属岳阳中西医结合医院、上海交通大学医学院附属瑞金医院北院、上海交通大学医学院附属第九人民医院诊断为骨髓增生异常综合征(myelodysplastic syndromes,MDS)患者120例,使用中心分层随机化方法,对满足DAC治疗要求的各危度MDS患者根据随机数字表进入西医组和中西医结合组,各60例。两组均给予相同的西医标准治疗,中西医结合组加以健脾补肾活血解毒方辨证加减治疗,比较两组患者西医、中西医结合的疗效及不良反应情况。结果本研究共收集120例,完成研究97例,其中西医组44例,中西医结合组53例。两组未出现完全缓解和部分缓解患者,西医疗效方面,西医组总有效率为25.0%,中西医结合组总有效率47.2%,中西医结合组总有效率高于西医组(P<0.05)。在中医证候评分情况方面,西医组总有效率为52.3%,中西医结合组总有效率为73.6%,中西医结合组总有效率高于西医组(P<0.05)。在生存质量方面,治疗后中西医结合组生活质量及卡氏评分改善优于西医组(P<0.05)。在安全性评价方面,两组不良反应率差异没有统计学意义(P>0.05)。结论健脾补肾活血解毒方联合DAC治疗方案在总有效率及生活质量等方面优于单纯应用DAC,且对于MDS患者中医症状改善更为明显。

补肾健脾通络方结合五行健骨操对老年骨质疏松脾肾两虚证患者骨密度、骨代谢及炎症水平的影响

目的:观察补肾健脾通络方结合五行健骨操对老年骨质疏松脾肾两虚证患者骨密度、骨代谢及炎症水平的影响。方法:选取100例老年骨质疏松脾肾两虚证患者,采用简单随机法分为两组。西药组给予碳酸钙D_(3)联合骨化三醇治疗,综合组在西药组基础上给予补肾健脾通络方结合五行健骨操干预。比较两组治疗前后动态平衡、骨密度、骨代谢、炎症水平及中医症候积分差异,统计不良反应。结果:综合组治疗后睁眼和闭眼的动态平衡参数低于西药组(均P<0.05)。综合组股骨颈和腰椎骨密度(BMD)及骨钙素(BGP)、总Ⅰ型前胶原氨基端前肽(T-PINP)、25-(OH)D_(3)治疗后较治疗前升高,综合组治疗后高于西药组(均P<0.05)。综合组C反应蛋白(CRP)、β-胶原特殊序列(β-CTX)、巨噬细胞集落刺激因子(M-CSF)、肿瘤坏死因子-α(TNF-α)治疗后较治疗前降低,综合组治疗后低于西药组(均P<0.05)。综合组中医症候积分治疗后较治疗前降低,综合组治疗后低于西药组(均P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论:补肾健脾通络方结合五行健骨操可减轻老年骨质疏松脾肾两虚证患者炎症反应,改善骨密度和骨代谢,提高平衡功能。

补肾健脾方治疗2型糖尿病合并血脂异常患者的疗效及对脂联素的影响研究

【目的】探讨补肾健脾方(主要由黄芪、淫羊藿、山药、丹参、鹿角胶、沙苑子、制何首乌、黄精、葛根、大黄等中药组成)对脾肾两虚型2型糖尿病(T2DM)合并血脂异常患者临床疗效及脂联素(adiponectin,ADP)的影响。【方法】将90例脾肾两虚型T2DM合并血脂异常患者随机分为西药治疗组(简称西药组)、中药治疗组(简称中药组)、中西医结合治疗组(简称联合组),每组各30例。3组患者均给予常规降糖治疗,在此基础上,西药组给予阿托伐他汀钙片口服治疗,中药组给予补肾健脾方治疗,联合组给予阿托伐他汀钙片联合补肾健脾方治疗,疗程为8周。观察3组患者治疗前后中医证候积分、糖脂代谢指标、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)及血清ADP水平的变化情况,并评价3组患者的中医证候疗效。【结果】(1)疗效方面,治疗8周后,西药组、中药组、联合组患者的总有效率分别为66.67%(20/30)、90.00%(27/30)、93.33%(28/30),组间比较,中药组和联合组的中医证候疗效均明显优于西药组(P<0.05)。(2)中医证候积分方面,治疗后,3组患者的中医证候积分均较治疗前下降(P<0.01),且中药组和联合组对中医证候积分的下降幅度均优于西药组(P<0.05或P<0.01)。(3)脂代谢方面,治疗后,3组患者的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前有不同程度的改善,其中TC、TG、LDL-C水平均较治疗前显著下降,HDL-C水平均较治疗前显著升高,差异均有统计学意义(P<0.05或P<0.01);组间比较,中药组对TC、LDL-C的下降幅度和对HDL-C的升高幅度均不及西药组和联合组(P<0.05或P<0.01)。(4)糖代谢方面,治疗后,中药组和联合组患者的空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、FINS、HOMA-IR水平均较治疗前显著下降(P<0.05或P<0.01),西药组患者仅FPG、2hPG、HOMA-IR水平较治疗前下降(P<0.05或P<0.01);组间比较,中药组和联合组患者对FPG、2hPG、HbA1c、FINS、HOMA-IR水平的下降幅度均明显优于西药组(P<0.05或P<0.01)。(5)脂肪激素方面,治疗后,3组患者的血清ADP水平均较治疗前显著升高(P<0.05或P<0.01),且中药组和联合组患者血清ADP水平的升高幅度均显著优于西药组(P<0.05)。【结论】补肾健脾方具有一定的调节脂质代谢作用,在改善脾肾两虚型T2DM合并血脂异常患者的临床症状、胰岛素抵抗,降低血糖,升高ADP水平等方面具有明显优势。

基于生物信息学和网络药理学探讨补肾健脾方改善2型糖尿病作用机制

目的 基于生物信息学和网络药理学探讨补肾健脾方治疗2型糖尿病(T2DM)的作用机制。方法 通过TCMSP、BATMAN-TCM数据库筛选补肾健脾方活性成分及作用靶点,通过GEO数据库获取T2DM相关数据集GSE18732和GSE19420,通过Mfuzz分析筛选与糖尿病同步变化的基因,作为T2DM疾病靶点。获取补肾健脾方与T2DM疾病靶点交集靶点,作为补肾健脾方治疗T2DM的作用靶点,通过STRING数据库构建靶点蛋白相互作用网络,筛选网络中的关键靶点,通过GO功能和KEGG通路富集分析其生物功能,对关键靶点进行单因素Logistic回归,筛选Hub基因,基于Hub基因构建T2DM预测模型。结果 获取补肾健脾方药物靶点1 837个,T2DM疾病靶点983个,药物-疾病交集靶点115个,主要富集于内分泌抵抗、胰岛素抵抗、胰岛素信号通路、非酒精性脂肪性肝病、细胞凋亡、细胞衰老、AMPK信号通路、糖尿病并发症中的AGE-RAGE信号通路和HIF-1信号通路。Hub基因有NFKB1和SREBF1,预测模型曲线下面积=0.829,具有良好的预测性能。结论 本研究综合生物信息学和网络药理学研究发现,补肾健脾方可能通过调控AMPK通路和AGE-RAGE等通路,发挥延缓T2DM进展作用,但仍需进一步实验验证。